BRAF-KIAA1549 (Kex15Bex9)

KIAA1549-BRAF · Variant type: fusion · Fusion partner: KIAA1549 (Kex15Bex9)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Ponatinib	99.6%	0.4%	78.23
2	Ripretinib	99.3%	0.7%	92.95
3	Dabrafenib	98.9%	1.1%	94.74
4	Encorafenib	98.6%	1.4%	98.50
5	Sorafenib	98.2%	1.8%	96.72
6	Vemurafenib	96.2%	3.8%	96.49
7	Regorafenib	96.0%	4.0%	95.99
8	Apatinib	91.9%	8.1%	97.73
9	Dasatinib	88.6%	11.4%	87.97
10	Pazopanib	78.2%	21.8%	97.49
11	Erdafitinib	70.3%	29.7%	95.71
12	Nilotinib	68.1%	31.9%	96.49
13	Umbralisib	58.8%	41.3%	98.74
14	Gedatolisib	56.5%	43.5%	99.75
15	Rabusertib	49.7%	50.3%	98.74
16	Dacomitinib	48.2%	51.8%	97.99
17	Pacritinib	48.2%	51.8%	88.64
18	Imatinib	47.9%	52.1%	99.00
19	Upadacitinib	45.7%	54.3%	97.98
20	Canertinib	42.0%	58.0%	96.49
21	Ibrutinib	36.3%	63.7%	94.74
22	Osimertinib	35.3%	64.7%	97.24
23	Lorlatinib	34.7%	65.3%	97.24
24	Tivozanib	34.0%	66.0%	92.42
25	Afatinib	33.7%	66.3%	98.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Ponatinib	99.6%	—	—
Ripretinib	99.3%	—	—
Dabrafenib	98.9%	—	—
Encorafenib	98.6%	—	—
Sorafenib	98.2%	—	—
Vemurafenib	96.2%	—	—
Regorafenib	96.0%	—	—
Apatinib	91.9%	—	—
Dasatinib	88.6%	—	—
Pazopanib	78.2%	—	—
Erdafitinib	70.3%	—	—
Nilotinib	68.1%	—	—
Umbralisib	58.8%	—	—
Gedatolisib	56.5%	—	—
Rabusertib	49.7%	—	—
Dacomitinib	48.2%	—	—
Pacritinib	48.2%	—	—
Imatinib	47.9%	—	—
Upadacitinib	45.7%	—	—
Canertinib	42.0%	—	—
Ibrutinib	36.3%	—	—
Osimertinib	35.3%	—	—
Lorlatinib	34.7%	—	—
Tivozanib	34.0%	—	—
Afatinib	33.7%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.2ms